title: Survival in women with grade 1 serous ovarian carcinoma.
abstract: OBJECTIVE
  To examine clinicopathologic variables associated with survival among women with low-grade (grade 1) serous ovarian carcinoma enrolled in a phase III study.
  
  
  METHODS
  This was an ancillary data analysis of Gynecologic Oncology Group protocol 182, a phase III study of women with stage III-IV epithelial ovarian carcinoma treated with carboplatin and paclitaxel compared with triplet or sequential doublet regimens. Women with grade 1 serous carcinoma (a surrogate for low-grade serous disease) were included in the analysis.
  
  
  RESULTS
  Among the 3,686 enrolled participants, 189 had grade 1 disease. The median age was 56.5 years and 87.3% had stage III disease. The median follow-up time was 47.1 months. Stratification according to residual disease after primary surgery was microscopic residual in 24.9%, 0.1-1.0 cm of residual in 51.3%, and more than 1.0 cm of residual in 23.8%. On multivariate analysis, only residual disease status (P=.006) was significantly associated with survival. Patients with microscopic residual had a significantly longer median progression-free (33.2 months) and overall survival (96.9 months) compared with those with residual 0.1-1.0 cm (14.7 months and 44.5 months, respectively) and more than 1.0 cm of residual disease (14.1 months and 42.0 months, respectively; progression-free and overall survival, P<.001). After adjustment for other variables, patients with low-grade serous carcinoma with measurable residual disease had a similar adjusted hazard ratio for death (2.12; P=.002) as their high-grade serous carcinoma counterparts with measurable disease (2.31; P<.001).
  
  
  CONCLUSIONS
  Surgical cytoreduction to microscopic residual was associated with improved progression-free and overall survival in women with advanced-stage low-grade serous ovarian carcinoma.
  
  
  BACKGROUND
  ClinicalTrials.gov, www.clinicaltrials.gov, NCT00011986.
  
  
  METHODS
  II.
authors: Johns Hopkins Medical Institutions, Baltimore, Maryland; the Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York; the University of California San Francisco, Comprehensive Cancer Center, San Francisco, and the University of California, Irvine Medical Center, Orange, California; the University of Arizona, Tucson, Arizona; and the University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors: Amanda
authors: A
authors: Nickles Fader
authors: James
authors: J
authors: Java
authors: Stefanie
authors: S
authors: Ueda
authors: Robert E
authors: RE
authors: Bristow
authors: Deborah K
authors: DK
authors: Armstrong
authors: Michael A
authors: MA
authors: Bookman
authors: David M
authors: DM
authors: Gershenson
mesh_terms: D000368:Aged; D018284:Cystadenocarcinoma, Serous / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D010053:Ovary / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology
references: Am J Surg Pathol. 2005 Feb;29(2):218-24
references: 15644779
references: Gynecol Oncol. 2003 Jun;89(3):447-52
references: 12798710
references: Cancer. 1998 Mar 1;82(5):893-901
references: 9486579
references: Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6
references: 17504374
references: Obstet Gynecol. 2006 Aug;108(2):361-8
references: 16880307
references: Hum Pathol. 1988 Sep;19(9):1030-5
references: 3417288
references: Am J Surg Pathol. 2005 Aug;29(8):1034-41
references: 16006797
references: J Natl Cancer Inst. 2003 Mar 19;95(6):484-6
references: 12644542
references: Mol Carcinog. 2003 Feb;36(2):53-9
references: 12557260
references: Curr Oncol Rep. 2008 Nov;10(6):519-23
references: 18928667
references: Oncogene. 2005 Feb 3;24(6):1053-65
references: 15558012
references: J Clin Oncol. 2009 Mar 20;27(9):1419-25
references: 19224846
references: Am J Surg Pathol. 2004 Apr;28(4):496-504
references: 15087669
references: J Pathol. 2004 Mar;202(3):336-40
references: 14991899
references: J Clin Oncol. 2007 Aug 20;25(24):3621-7
references: 17704411
references: Cancer. 2012 Jun 15;118(12):3087-94
references: 22072418
references: Int J Gynecol Cancer. 1993 Mar;3(2):72-79
references: 11578325
references: Lancet Oncol. 2013 Feb;14(2):134-40
references: 23261356
references: Anal Quant Cytol Histol. 1986 Dec;8(4):349-53
references: 3814302
references: Gynecol Oncol. 2006 Nov;103(2):703-8
references: 16828848
references: Am J Surg Pathol. 2007 Aug;31(8):1168-74
references: 17667538
references: Cancer Res. 2005 Nov 15;65(22):10602-12
references: 16288054
references: Stat Med. 1993 Dec 30;12(24):2257-71
references: 8134732
references: J Clin Oncol. 2003 Sep 1;21(17):3194-200
references: 12860964
references: Int J Gynecol Pathol. 2003 Jan;22(1):37-41
references: 12496696
references: Rev Obstet Gynecol. 2010 Summer;3(3):111-7
references: 21364862
references: Ann Surg Oncol. 2012 Dec;19(13):4059-67
references: 22766983